Search

Your search keyword '"Feugier, A."' showing total 48 results
Start Over Author "Feugier, A." Journal hematological oncology
48 results on '"Feugier, A."'

1. Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.

Author

Carras, S., primary, Torroja, A., additional, Emadali, A., additional, Daguindau, N., additional, Tempescul, A., additional, Macro, M., additional, Moreau, A., additional, Tchernonog, E., additional, Houot, R., additional, Schmitt, A., additional, Dartigeas, C., additional, Dupuis, J., additional, Jardin, F., additional, Banos, A., additional, Corm, S., additional, Barbieux, S., additional, Zerazhi, H., additional, Arkam, Y., additional, Fouillet, L., additional, Fontan, J., additional, Vilque, J., additional, Moles, M., additional, Sarkozy, C., additional, Morineau, N., additional, Joly, B., additional, Voillat, L., additional, Alexis, M., additional, Fornecker, L. M., additional, Garidi, R., additional, Amorim, S., additional, Bouabdallah, K., additional, Dorvaux, V., additional, Chabrot, C., additional, Feugier, P., additional, Damaj, G., additional, Fleury, J., additional, Delwail, V., additional, Ysebaert, L., additional, Burroni, B., additional, Callanan, M., additional, Legouill, S., additional, and Gressin, R., additional

Published
2023
Full Text
View/download PDF

2. RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA

Author

Rebaud, L., primary, Capobianco, N., additional, Spottiswoode, B., additional, Cottereau, A., additional, Trotman, J., additional, Feugier, P., additional, Nastoupil, L. J., additional, Bachy, E., additional, Flinn, I. W., additional, Haioun, C., additional, Ysebaert, L., additional, Bartlett, N. L., additional, Tilly, H., additional, Casasnovas, R., additional, Ricci, R., additional, Portugues, C., additional, Meignan, M., additional, Morschhauser, F., additional, and Buvat, I., additional

Published
2023
Full Text
View/download PDF

3. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Author

Houot, R., primary, Bachy, E., additional, Cartron, G., additional, Gros, F., additional, Morschhauser, F., additional, Oberic, L., additional, Gastinne, T., additional, Feugier, P., additional, Dulery, R., additional, Thieblemont, C., additional, Joris, M., additional, Jardin, F., additional, Choquet, S., additional, Casasnovas, O., additional, Brisou, G., additional, Cheminant, M., additional, Bay, J., additional, Gutierrez, F. Llamas, additional, Menard, C., additional, Tarte, K., additional, Delfau, M., additional, Itti, E., additional, Bailly, C., additional, Al Tabaa, Y., additional, Laurent, C., additional, and Lemonnier, F., additional

Published
2023
Full Text
View/download PDF

4. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)

Author

Emanuele Zucca, Monica Tani, Guido Gini, Annarita Conconi, Roch Houot, O. Casasnovas, Alessandro Pulsoni, Michele Spina, Francesco Merli, Luca Baldini, Remy Gressin, Catherine Thieblemont, Maria Giuseppina Cabras, B. De Renzis, Manuela Zanni, Guillaume Cartron, F. Esposito, U. Occhini, Corinne Haioun, Dario Marino, F. Palombi, Hervé Ghesquières, Annalia Molinari, Hervé Tilly, Federica Cavallo, Liliana Devizzi, Lorella Orsucci, F. Morschhauser, S. Le Gouill, E. Gyan, Michele Merli, Davide Rossi, Francesco Angrilli, Stefano Luminari, Giuseppe Pietrantuono, Maria Cristina Pirosa, Anastasios Stathis, N. Ielmini, Francesco Bertoni, Franco Cavalli, Gerardo Musuraca, Francesca Re, P. Feugier, Enrico Capochiani, Anna Marina Liberati, and Catello Califano

Subjects
Cancer Research, medicine.medical_specialty, Chlorambucil, business.industry, MALT lymphoma, Hematology, General Medicine, medicine.disease, Gastroenterology, Oncology, Internal medicine, medicine, Rituximab, business, medicine.drug
Published
2021
Full Text
View/download PDF

5. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15)

Author

Catherine Thieblemont, P. Feugier, F. Morschhauser, Vanessa Szablewski, H. Tilly, Stéphanie Becker, Kamal Bouabdallah, Guillaume Cartron, Olivier Casasnovas, and Marie Maerevoet

Subjects
Cancer Research, Oncology, business.industry, Phase (matter), Relapsed refractory, Cancer research, Medicine, Hematology, General Medicine, business, B-cell lymphoma, medicine.disease
Published
2021
Full Text
View/download PDF

6. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

E. Gyan, Ghandi Damaj, H. Tilly, David Sibon, S. Le Gouill, Nadine Morineau, Charles Herbaux, Catherine Thieblemont, P. Feugier, Roch Houot, Loic Ysebaert, Guillaume Cartron, Corinne Haioun, E. Nicolas Virelizier, Remy Gressin, Karin Tarte, J. M. Schiano de Colella, O. Casasnovas, F. Morschhauser, Stéphanie Guidez, Emmanuel Bachy, and Camille Laurent

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Venetoclax, Hematology, General Medicine, chemistry.chemical_compound, chemistry, Obinutuzumab, Atezolizumab, Internal medicine, medicine, In patient, Refractory Follicular Lymphoma, business
Published
2021
Full Text
View/download PDF

8. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY

Author

Julien Lazarovici, Michel Meignan, Driss Chaoui, Hervé Ghesquières, C. Borel, Alain Delmer, Christophe Bonnet, T. Lamy, Benoit Tessoulin, A. Traverse Glehen, Anne-Claire Gac, Pierre Feugier, Kamal Bouabdallah, Aspasia Stamatoullas, F. Bras, Pauline Brice, Olivier Casasnovas, J. M. Shiano del colella, Luc‐M. Fornecker, Thomas Gastinne, and H. Moatti

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Consolidation (soil), business.industry, Phases of clinical research, Hematology, General Medicine, Classical Hodgkin's Lymphoma, Stage i ii, ABVD, Internal medicine, medicine, In patient, Brentuximab vedotin, business, medicine.drug
Published
2021
Full Text
View/download PDF

9. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

Author

Catherine Thieblemont, Guillaume Cartron, Gilles Salles, René-Olivier Casasnovas, L. Vercellino, Fabrice Jardin, M.H. Delfau-Larue, A. Cottereau, Gandhi Damaj, Mathieu Viennot, Vincent Ribrag, Elodie Bohers, L Renaud, R. Bouabdallah, C Portugues, P. Feugier, F. Morschhauser, E. Nicolas-Virelizier, H. Tilly, Michel Meignan, Pierre-Julien Viailly, Corinne Haioun, and Loïc Chartier

Subjects
Cancer Research, Oncology, business.industry, Circulating tumor DNA, Cancer research, Medicine, Hematology, General Medicine, Metabolic tumor volume, business, medicine.disease, Diffuse large B-cell lymphoma
Published
2021
Full Text
View/download PDF

10. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL

Author

Ghandi Damaj, Christophe Bonnet, T. Vander Borght, Diane Coso, Serge Bologna, Laure Lebras, Frederic Peyrade, J. N Bastie, Pierre Olivier, David Sibon, B. Fabiani, Herve Ghesquieres, Catherine Thieblemont, F. Morschhauser, Stéphanie Becker, Vincent Ribrag, H. Tilly, Josette Brière, P. Feugier, and Corinne Haioun

Subjects
Cancer Research, Materials science, Nuclear magnetic resonance, Oncology, medicine.diagnostic_test, Positron emission tomography, Phase (matter), medicine, Hematology, General Medicine, medicine.disease, Diffuse large B-cell lymphoma
Published
2021
Full Text
View/download PDF

11. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15)

Author

Maerevoet, M., primary, Casasnovas, O., additional, Cartron, G., additional, Morschhauser, F., additional, Thieblemont, C., additional, Bouabdallah, K., additional, Feugier, P., additional, Szablewski, V., additional, Becker, S., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

12. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY

Author

Gastinne, T., primary, Bouabdallah, K., additional, Moatti, H., additional, Tessoulin, B., additional, Shiano del colella, J. M., additional, Lamy, T., additional, Casasnovas, O., additional, Borel, C., additional, Stamatoullas, A., additional, Gac, A. C., additional, Chaoui, D., additional, Feugier, P., additional, Delmer, A., additional, Bonnet, C., additional, Fornecker, Luc‐M., additional, Lazarovici, J., additional, Bras, F., additional, Ghesquieres, H., additional, Meignan, M., additional, Traverse Glehen, A., additional, and Brice, P., additional

Published
2021
Full Text
View/download PDF

13. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Cartron, G., primary, Bachy, E., additional, Guidez, S., additional, Gyan, E., additional, Gressin, R., additional, Morineau, N., additional, Sibon, D., additional, Casasnovas, O., additional, Le Gouill, S., additional, Tilly, H., additional, Ysebaert, L., additional, Schiano de Colella, J. M., additional, Feugier, P., additional, Virelizier, E. Nicolas, additional, Haioun, C., additional, Damaj, G., additional, Tarte, K., additional, Laurent, C., additional, Houot, R., additional, Thieblemont, C., additional, Morschhauser, F., additional, and Herbaux, C., additional

Published
2021
Full Text
View/download PDF

14. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

Author

Bohers, E, primary, Delfau‐Larue, M, additional, Vercellino, L, additional, Cottereau, A, additional, Viennot, M, additional, Viailly, P, additional, Salles, G, additional, Tilly, H, additional, Damaj, G, additional, Haioun, C, additional, Ribrag, V, additional, Morschhauser, F, additional, Casasnovas, R, additional, Nicolas‐Virelizier, E, additional, Feugier, P, additional, Bouabdallah, R, additional, Cartron, G, additional, Renaud, L, additional, Chartier, L, additional, Portugues, C, additional, Meignan, M, additional, Jardin, F, additional, and Thieblemont, C, additional

Published
2021
Full Text
View/download PDF

15. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)

Author

Pirosa, M. C., primary, Orsucci, L., additional, Feugier, P., additional, Tani, M., additional, Ghesquieres, Hervé, additional, Musuraca, G., additional, Baldini, L., additional, Merli, F., additional, Renzis, B., additional, Gyan, E., additional, Gini, G., additional, Marino, D., additional, Gressin, R., additional, Morschhauser, F., additional, Palombi, F., additional, Cavallo, F., additional, Conconi, A., additional, Gouill, S., additional, Tilly, Hervé, additional, Zanni, M., additional, Cabras, M. G., additional, Capochiani, E., additional, Califano, C., additional, Molinari, A. L., additional, Pulsoni, A., additional, Angrilli, F., additional, Cartron, G., additional, Casasnovas, O., additional, Devizzi, L., additional, Haioun, C., additional, Houot, R., additional, Liberati, A. M., additional, Occhini, U., additional, Merli, M., additional, Pietrantuono, G., additional, Re, F., additional, Spina, M., additional, Esposito, F., additional, Bertoni, F., additional, Rossi, D., additional, Ielmini, N., additional, Luminari, S., additional, Cavalli, F., additional, Zucca, E., additional, Stathis, A., additional, and Thieblemont, C., additional

Published
2021
Full Text
View/download PDF

16. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Herbaux, C., primary, Schiano de Colella, J. M., additional, Thieblemont, C., additional, Guidez, S., additional, Ysebaert, L., additional, Tilly, H., additional, Gouill, S., additional, Houot, R., additional, Bachy, E., additional, Laurent, C., additional, Damaj, G., additional, Feugier, P., additional, Morineau, N., additional, Tarte, K., additional, Morschhauser, F., additional, and Cartron, G., additional

Published
2021
Full Text
View/download PDF

17. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL

Author

Bologna, S, primary, Vander Borght, T, additional, Briere, J, additional, Ribrag, V, additional, Damaj, G. L, additional, Thieblemont, C, additional, Feugier, P, additional, Peyrade, F, additional, Lebras, L, additional, Coso, D, additional, Sibon, D, additional, Bonnet, C, additional, Morschhauser, F, additional, Ghesquieres, H, additional, Becker, S, additional, Olivier, P, additional, Fabiani, B, additional, Tilly, H, additional, Haioun, C, additional, and Bastie, J. N, additional

Published
2021
Full Text
View/download PDF

18. EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.

Author

Delfau‐Larue, M., Viailly, P., Cartron, G., Morschhauser, F., Gros, F., Gastinne, T., Oberic, L., Bachy, E., Dulery, R., Feugier, P., Menard, C., Quelen, C., Pangault, C., Portugues, C., Gomes, L., Itti, E., Bailly, C., Lemonnier, F., Laurent, C., and Houot, R.

Subjects
CIRCULATING tumor DNA, T cells, LYMPHOMAS
Abstract

EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY B Introduction: b CAR T-cells have significantly improved the outcome of patients with relapsed or refractory ( I R i / I R i ) large B-cell lymphoma (LBCL). The aim of our study was to monitor ctDNA before and after CAR T-cell infusion and correlate the results with clinical outcome in the ALYCANTE trial. [Extracted from the article]

Published
2023
Full Text
View/download PDF

19. Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Author

Kossar Hosseini, Julien Broséus, Marc Muller, Gabrielle Roth-Guepin, Pierre Feugier, Christine Rotonda, Marie-Christine Béné, Aurore Perrot, Caroline Bonmati, Lauriane Filliatre-clement, Luciane Schirmer, Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Génétique [CHRU Nancy], Plateforme d'Aide à la Recherche Clinique [CHRU Nancy] (PARC), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service d'Hématologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Service d’Hématologie Adulte [Hôpitaux de Brabois, CHU Nancy], and CHU de Nancy - Hôpitaux de Brabois

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Prognostic factor, Anthracycline, serum albumin, Serum albumin, Nutritional Status, body mass index, Kaplan-Meier Estimate, Overweight, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, In patient, ComputingMilieux_MISCELLANEOUS, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, 2. Zero hunger, biology, business.industry, Hematology, General Medicine, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Obesity, 3. Good health, Leukemia, Myeloid, Acute, Oncology, 030220 oncology & carcinogenesis, biology.protein, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, acute myeloblastic leukaemia, medicine.symptom, Acute myeloblastic leukaemia, business, Body mass index, Biomarkers, 030215 immunology
Abstract

International audience; Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and body mass index (BMI). These two parameters could have a value as prognostic factors to guide patients' management. We evaluated the association between SA levels, BMI, and survival, evaluated as overall survival (OS) and event-free survival. Furthermore, we investigated the association between BMI, SA, and other prognostic factors of interest in AML. This retrospective single-center study included 159 patients diagnosed with AML at Nancy Hospital between 2005 and 2013, treated with aracytine and anthracycline. Forty-four percent of patients presented with normal weight while 56% were obese/overweight. Serum albumin levels were

Published
2018
Full Text
View/download PDF

20. IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY

Author

Ian W. Flinn, Nathalie Spielewoy, F. Morschhauser, Robin Gasiorowski, S. de Vos, Marek Trněný, Richard Greil, Gilles Salles, Martin Kornacker, Jean-François Larouche, Arijit Sinha, P. Feugier, Farheen Mir, Elizabeth Punnoose, Árpád Illés, Nathalie A. Johnson, Caterina Patti, Pieternella J. Lugtenburg, Adam M. Petrich, Andrew D. Zelenetz, Divya Samineni, Alexandra Bazeos, Kathryn Humphrey, and Edith Szafer-Glusman

Subjects
Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Hematology, General Medicine, medicine.disease, Gastroenterology, chemistry.chemical_compound, Oncology, chemistry, Internal medicine, Ven, medicine, In patient, business, Diffuse large B-cell lymphoma
Published
2019
Full Text
View/download PDF

21. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study

Author

Phi Linh Nguyen-Thi, Loic Ysebaert, Marie C. Béné, Jehan Dupuis, Daniel Re, Godelieve Meunier, Pierre Feugier, Richard Lemal, Thérèse Aurran, Stéphane Leprêtre, Annie Brion, Bruno Cazin, Cécile Tomowiak, Guillaume Cartron, Anne Sophie Michallet, Véronique Leblond, Florence Cymbalista, Anne Quinquenel, Marie Sarah Dilhuydy, and Pierre Morel

Subjects
Bendamustine, Cancer Research, medicine.medical_specialty, Chronic lymphocytic leukemia, Population, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, education, education.field_of_study, Chlorambucil, business.industry, Retrospective cohort study, Hematology, General Medicine, medicine.disease, 3. Good health, Surgery, Leukemia, Oncology, 030220 oncology & carcinogenesis, Cohort, Rituximab, business, 030215 immunology, medicine.drug
Abstract

The mean age at diagnosis of chronic lymphocytic leukemia (CLL) is 72 years, with 22.8% of patients being older than 80 years. However, the elderly are underrepresented in clinical studies of CLL. We performed a retrospective study of CLL patients aged 80 years or older at the initiation of first-line therapy in hospitals affiliated with the French intergroup on CLL (French Innovative Leukemia Organization) between 2003 and 2013. Here, we describe the clinical and biological characteristics, treatment, and outcomes for 201 patients. The median age of the cohort was 83.2 years (80-92 years). The median Cumulative Index Rating Scale comorbidity score was 5 and the median creatinine clearance was 48 mL/min (Cockcroft-Gault formula). At treatment initiation, Binet stage was A (26.4%), B (27.9%), or C (40.3%). Therapy consisted mainly of chlorambucil (65.7%), bendamustine (10.5%), and rituximab (44.3%) as follows: chlorambucil alone (45.3%) or immunochemotherapy (48.3%) with rituximab + chlorambucil (22.7%), rituximab + bendamustine (10.4%), or rituximab + cyclophosphamide + dexamethasone (5.5%). The overall response rate was 66.2% with 31.8% clinical complete remission. The median overall and progression-free survival from treatment initiation was 53.7 and 18.3 months, respectively. These results suggest that treatment is feasible in this age group, even with immunochemotherapy. Thus, prospective trials should target this population and oncogeriatric evaluation and new targeted therapies should be part of such future trials.

Published
2016
Full Text
View/download PDF

22. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA

Author

Armando López-Guillermo, Sarah Huet, David Gentien, E. Campo, A. Viari, Alexandra Traverse-Glehen, Luc Xerri, S. Boyault, Fabrice Jardin, Gilles Salles, A.L. Feldman, Brian K. Link, Laura Magnano, B. Tesson, James R. Cerhan, Corinne Haioun, E. Thomas, Jean-Philippe Jais, S. M. Ansell, Fritz Offner, Karin Tarte, Benoit Albaud, S. Hayette, P. Feugier, and Pauline Brice

Subjects
Cancer Research, business.industry, Disease progression, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Gene expression profiling, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, Medicine, business, 030215 immunology
Published
2017
Full Text
View/download PDF

23. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY

Author

R. Bouabdallah, A. Lopez, S. Snauwaert, H. Gonzalez, Gilles Salles, Michael Simon, P. Gaulard, Bernadette Corront, H. Tilly, Catherine Sebban, Catherine Thieblemont, B. Choufi, L. Roulin, G.M. Pica, F. Morschhauser, Judith Trotman, O. Casasnovas, Olivier Fitoussi, Michel Meignan, Pascal Godmer, A. Cottereau, Christiane Copie-Bergman, Margaret Macro, P. Feugier, J. Abraham, Christophe Fruchart, Lucie Oberic, Josette Briere, L. Vercellino, Vincent Ribrag, and L. Sahnes

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, General Medicine, Metabolic tumor volume, business, Baseline (configuration management)
Published
2019
Full Text
View/download PDF

24. RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY

Author

Luc Xerri, J.C. Eisenmann, T. Lamy de la Chapelle, H. Tilly, Vincent Ribrag, Loic Ysebaert, Gilles Salles, Hervé Maisonneuve, Corinne Haioun, H. Jardel, Pierre Feugier, M.H. Delfau-Larue, F. Morschhauser, G. Cartron, M.L. Boulland, Thierry Fest, Sylvie Glaisner, Olivier Casasnovas, S. Le Gouil, and G.M. Pica

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Follicular lymphoma, Molecular Disease, Ancillary Study, Hematology, General Medicine, medicine.disease, Internal medicine, Medicine, Rituximab, business, medicine.drug, Lenalidomide
Published
2019
Full Text
View/download PDF

25. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

Author

Sophie Bernard, Caterina Stelitano, Catherine Thieblemont, Kamal Bouabdallah, Michele Merli, M. Ponzoni, Anna Marina Liberati, Alexandra Traverse-Glehen, Emanuele Zucca, Sacchi Samantha Pozzi, K. Beldjord, Emilio Iannitto, Pierre Feugier, M. Ladetto, Benoit Tessoulin, Lucile Baseggio, Marina Cesaretti, Daniela Drandi, Barbara Castagnari, Claudio Tripodo, Remy Gressin, Maria Giuseppina Cabras, Simone Ferrero, Isabel Alvarez, and C. Patti

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Medicine, Phases of clinical research, Hematology, General Medicine, Splenic marginal zone lymphoma, Radiology, business, medicine.disease, Minimal residual disease
Published
2019
Full Text
View/download PDF

27. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY

Author

Cottereau, A., primary, Vercellino, L., additional, Casasnovas, O., additional, Tilly, H., additional, Feugier, P., additional, Fruchart, C., additional, Roulin, L., additional, Oberic, L., additional, Pica, G., additional, Ribrag, V., additional, Abraham, J., additional, Simon, M., additional, Gonzalez, H., additional, Bouabdallah, R., additional, Fitoussi, O., additional, Sebban, C., additional, Lopez, A., additional, Macro, M., additional, Sahnes, L., additional, Morschhauser, F., additional, Trotman, J., additional, Corront, B., additional, Choufi, B., additional, Snauwaert, S., additional, Godmer, P., additional, Copie-Bergman, C., additional, Briere, J., additional, Salles, G., additional, Gaulard, P., additional, Meignan, M., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

28. IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY

Author

Morschhauser, F., primary, Flinn, I.W., additional, Gasiorowski, R., additional, Illés, Á., additional, Feugier, P., additional, Greil, R., additional, Johnson, N.A., additional, Larouche, J., additional, Lugtenburg, P.J., additional, Patti, C., additional, Salles, G., additional, Trněný, M., additional, de Vos, S., additional, Mir, F., additional, Kornacker, M., additional, Punnoose, E.A., additional, Samineni, D., additional, Szafer-Glusman, E., additional, Petrich, A., additional, Sinha, A., additional, Spielewoy, N., additional, Humphrey, K., additional, Bazeos, A., additional, and Zelenetz, A.D., additional

Published
2019
Full Text
View/download PDF

29. RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY

Author

Delfau-Larue, M.H., primary, Boulland, M.L., additional, Feugier, P., additional, Maisonneuve, H., additional, Casasnovas, O., additional, Haioun, C., additional, Pica, G.M., additional, Lamy de la Chapelle, T., additional, Ysebaert, L., additional, Tilly, H., additional, Eisenmann, J.C., additional, Le Gouil, S., additional, Ribrag, V., additional, Jardel, H., additional, Glaisner, S., additional, Cartron, G., additional, Salles, G., additional, Xerri, L., additional, Fest, T., additional, and Morschhauser, F., additional

Published
2019
Full Text
View/download PDF

30. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

Author

Ferrero, S., primary, Ladetto, M., additional, Beldjord, K., additional, Drandi, D., additional, Stelitano, C., additional, Bernard, S., additional, Castagnari, B., additional, Bouabdallah, K., additional, Cesaretti, M., additional, Alvarez, I., additional, Gressin, R., additional, Ponzoni, M., additional, Tripodo, C., additional, Traverse-Glehen, A., additional, Baseggio, L., additional, Liberati, A., additional, Merli, M., additional, Tessoulin, B., additional, Patti, C., additional, Cabras, M., additional, Feugier, P., additional, Pozzi, S., additional, Zucca, E., additional, Iannitto, E., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

31. SAFETY AND EFFICACY OF ATEZOLIZUMAB, OBINUTUZUMAB AND VENETOCLAX COMBINATION FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMAS: RESULTS FROM THE SAFETY-RUN OF A LYSA STUDY

Author

H. Tilly, F. Morschhauser, Guillaume Cartron, P. Feugier, Charles Herbaux, S. Le Gouill, Gilles Salles, and Remy Gressin

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Hematology, General Medicine, chemistry.chemical_compound, chemistry, Obinutuzumab, Atezolizumab, Internal medicine, Relapsed refractory, medicine, business
Published
2019
Full Text
View/download PDF

32. Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Author

Filliatre‐Clement, Lauriane, primary, Broseus, Julien, additional, Muller, Marc, additional, Hosseini, Kossar, additional, Rotonda, Christine, additional, Schirmer, Luciane, additional, Roth‐Guepin, Gabrielle, additional, Bonmati, Caroline, additional, Feugier, Pierre, additional, Béné, Marie‐Christine, additional, and Perrot, Aurore, additional

Published
2018
Full Text
View/download PDF

33. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study

Author

Godelieve, Meunier, Loic, Ysebaert, Phi Linh, Nguyen-Thi, Stéphane, Lepretre, Anne, Quinquenel, Jehan, Dupuis, Richard, Lemal, Thérèse, Aurran, Cécile, Tomowiak, Florence, Cymbalista, Marie Sarah, Dilhuydy, Annie, Brion, Pierre, Morel, Bruno, Cazin, Véronique, Leblond, Guillaume, Cartron, Daniel, Ré, Marie Christine, Béné, Anne Sophie, Michallet, and Pierre, Feugier

Subjects
Aged, 80 and over, Chromosome Aberrations, Male, Age Factors, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Treatment Outcome, Socioeconomic Factors, Antineoplastic Combined Chemotherapy Protocols, Mutation, Humans, Female, Biomarkers, Neoplasm Staging, Retrospective Studies
Abstract

The mean age at diagnosis of chronic lymphocytic leukemia (CLL) is 72 years, with 22.8% of patients being older than 80 years. However, the elderly are underrepresented in clinical studies of CLL. We performed a retrospective study of CLL patients aged 80 years or older at the initiation of first-line therapy in hospitals affiliated with the French intergroup on CLL (French Innovative Leukemia Organization) between 2003 and 2013. Here, we describe the clinical and biological characteristics, treatment, and outcomes for 201 patients. The median age of the cohort was 83.2 years (80-92 years). The median Cumulative Index Rating Scale comorbidity score was 5 and the median creatinine clearance was 48 mL/min (Cockcroft-Gault formula). At treatment initiation, Binet stage was A (26.4%), B (27.9%), or C (40.3%). Therapy consisted mainly of chlorambucil (65.7%), bendamustine (10.5%), and rituximab (44.3%) as follows: chlorambucil alone (45.3%) or immunochemotherapy (48.3%) with rituximab + chlorambucil (22.7%), rituximab + bendamustine (10.4%), or rituximab + cyclophosphamide + dexamethasone (5.5%). The overall response rate was 66.2% with 31.8% clinical complete remission. The median overall and progression-free survival from treatment initiation was 53.7 and 18.3 months, respectively. These results suggest that treatment is feasible in this age group, even with immunochemotherapy. Thus, prospective trials should target this population and oncogeriatric evaluation and new targeted therapies should be part of such future trials.

Published
2016

34. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL

Author

Jehan Dupuis, Selim Corm, Remy Gressin, Roch Houot, Christiane Mounier, Sylvain Carras, Caroline Dartigeas, M. Macro, Ghandi Damaj, Nicolas Daguindau, Mary Callanan, Jean-Michel Pignon, Anne-Sophie Moreau, S. Le Gouill, Adrien Tempescul, P. Feugier, Fabrice Jardin, Guillaume Cartron, Luc Mathieu Fornecker, I. Ysebaert, A. Bannos, Lionel Karlin, J. Fleury, Anna Schmitt, and Cecile Chabrot

Subjects
Cancer Research, Pediatrics, medicine.medical_specialty, Group trial, business.industry, Hematology, General Medicine, First line treatment, 03 medical and health sciences, Regimen, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Molecular Response, Internal medicine, medicine, business, 030215 immunology
Published
2017
Full Text
View/download PDF

35. A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA

Author

Roch Houot, E. Van Den Neste, Luc Xerri, A. Van Hoof, Christophe Bonnet, S. Le Gouill, Franck Morschhauser, B. Fabiani, Guillaume Cartron, R. Bouabdallah, P. Feugier, K. Van Eygen, H. Tilly, E. Nicolas-Virelizier, F. Bijou, Corinne Haioun, and Gilles Salles

Subjects
0301 basic medicine, Cancer Research, business.industry, Hematology, General Medicine, medicine.disease, Lymphoma, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, Oncology, chemistry, Refractory, Obinutuzumab, 030220 oncology & carcinogenesis, medicine, Cancer research, Follicular B cell, business, Lenalidomide, medicine.drug
Published
2017
Full Text
View/download PDF

36. EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL

Author

Elizabeth Punnoose, L. Tonon, Sarah Huet, Hervé Tilly, Luc Xerri, B. Tesson, A. Viari, Christopher R. Bolen, Jeffrey M. Venstrom, P. Feugier, Gilles Salles, Edith Szafer-Glusman, and Pauline Brice

Subjects
Oncology, Gynecology, Cancer Research, medicine.medical_specialty, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Outcome (game theory), 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, 030215 immunology
Published
2017
Full Text
View/download PDF

37. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group

Author

Le Gouill, S., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Dartigeas, C., additional, Damaj, G., additional, Gastinne, T., additional, Ribrag, V., additional, Feugier, P., additional, Casasnovas, O., additional, Zerazhi, H., additional, Haioun, C., additional, Maisonneuve, H., additional, Van Den Neste, E., additional, Tournilhac, O., additional, Le Dû, K., additional, Morschhauser, F., additional, Cartron, G., additional, Fornecker, L., additional, Salles, G., additional, Tilly, H., additional, Lamy, T., additional, Gressin, R., additional, and Hermine, O., additional

Published
2017
Full Text
View/download PDF

38. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE

Author

Ribrag, V., primary, Feugier, P., additional, Doorduijn, J., additional, Delfau-Larue, M., additional, Hermine, O., additional, Kluin-Nelemans, H., additional, Dasilva, M., additional, Lopez-Hernandez, A., additional, Walewski, J., additional, Szymczyk, M., additional, Pott, C., additional, Homburg, C., additional, Van der Velden, V., additional, Gameiro, P., additional, Garcia-Sanz, R., additional, Ladetto, M., additional, van Krieken, H., additional, Cabeçadas, J., additional, Rymkiewicz, G., additional, Klapper, W., additional, Hoster, E., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2017
Full Text
View/download PDF

39. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL

Author

Gressin, R., primary, Daguindau, N., additional, Tempescul, A., additional, Moreau, A., additional, Carras, S., additional, Cartron, G., additional, Schmitt, A., additional, Houot, R., additional, Dartigeas, C., additional, Pignon, J., additional, Corm, S., additional, Bannos, A., additional, Mounier, C., additional, Dupuis, J., additional, Macro, M., additional, Fleury, J., additional, Jardin, F., additional, Karlin, L., additional, Damaj, G., additional, Feugier, P., additional, Fornecker, L., additional, Chabrot, C., additional, Ysebaert, I., additional, Callanan, M., additional, and Le Gouill, S., additional

Published
2017
Full Text
View/download PDF

40. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA

Author

Huet, S., primary, Tesson, B., additional, Jais, J., additional, Feldman, A.L., additional, Magnano, L., additional, Thomas, E., additional, Traverse-Glehen, A., additional, Albaud, B., additional, Xerri, L., additional, Ansell, S., additional, Tarte, K., additional, Boyault, S., additional, Haioun, C., additional, Link, B., additional, Feugier, P., additional, Lopez-Guillermo, A., additional, Brice, P., additional, Hayette, S., additional, Jardin, F., additional, Offner, F., additional, Gentien, D., additional, Viari, A., additional, Campo, E., additional, Cerhan, J.R., additional, and Salles, G., additional

Published
2017
Full Text
View/download PDF

42. A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA

Author

Morschhauser, F., primary, Le Gouill, S., additional, Feugier, P., additional, Van Den Neste, E., additional, Nicolas-Virelizier, E., additional, Bijou, F., additional, Salles, G.A., additional, Tilly, H., additional, Van Eygen, K., additional, Van Hoof, A., additional, Bonnet, C., additional, Haioun, C., additional, Bouabdallah, R., additional, Fabiani, B., additional, Xerri, L., additional, Cartron, G., additional, and Houot, R., additional

Published
2017
Full Text
View/download PDF

43. KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA.

Author

Cheminant, M., Carras, S., Bruneau, J., Lemonnier, F., Bachy, E., Herbaux, C., Feugier, P., Daguindau, N., Gastinne, T., Guillermin, Y., Lamarque, M., Slama, B., Wolfromm, A., Morschhauser, F., Tournilhac, O., Gaulard, P., Asnafi, V., Ortonne, N., Damaj, G., and Hermine, O.

Subjects
T-cell lymphoma, KILLER cells
Abstract

KILT: A RANDOMIZED NON-COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA B Background: b Peripheral T-cell Lymphoma (PTCL) is a heterogeneous group of mature T-cell lymphomas (TCL) with adverse outcomes. KIR3DL2 is a killer immunoglobulin-like receptor that is expressed across different subtypes of TCL, including approximately 40% of PTCL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

44. Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Author

Filliatre‐Clement, Lauriane, Broseus, Julien, Muller, Marc, Hosseini, Kossar, Rotonda, Christine, Schirmer, Luciane, Roth‐Guepin, Gabrielle, Bonmati, Caroline, Feugier, Pierre, Béné, Marie‐Christine, Perrot, Aurore, Filliatre-Clement, Lauriane, Roth-Guepin, Gabrielle, and Béné, Marie-Christine

Subjects
PROGNOSIS, SERUM albumin, SURVIVAL analysis (Biometry), BODY mass index, ACUTE myeloid leukemia, PROPORTIONAL hazards models, RETROSPECTIVE studies, KAPLAN-Meier estimator, NUTRITIONAL status
Abstract

Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and body mass index (BMI). These two parameters could have a value as prognostic factors to guide patients' management. We evaluated the association between SA levels, BMI, and survival, evaluated as overall survival (OS) and event-free survival. Furthermore, we investigated the association between BMI, SA, and other prognostic factors of interest in AML. This retrospective single-center study included 159 patients diagnosed with AML at Nancy Hospital between 2005 and 2013, treated with aracytine and anthracycline. Forty-four percent of patients presented with normal weight while 56% were obese/overweight. Serum albumin levels were <30 g/L for 49 patients, and ≥30 g/L for 110. Thirty-four patients with low SA levels were also obese. Favourable OS was associated with SA levels ≥30 g/L (HR = 0.467; 95% CI 0.230-0.946; P = .034) but was not impacted by the BMI. Serum albumin levels appear to be an independent prognostic factor in AML and a better parameter than BMI for evaluating the nutritional status of patients at diagnosis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE

Author

V H J van der Velden, José Cabeçadas, Wolfram Klapper, C. Homburg, M.H. Delfau-Larue, Ramón García-Sanz, Hanneke C. Kluin-Nelemans, H. van Krieken, A. Lopez-Hernandez, S. Le Gouill, M. Dasilva, Olivier Hermine, C. Pott, M. Ladetto, Martin Dreyling, Michal Szymczyk, Eva Hoster, Paula Gameiro, Jan Walewski, J.K. Doorduijn, P. Feugier, Vincent Ribrag, and Grzegorz Rymkiewicz

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Physical therapy, Rituximab, business, 030215 immunology, medicine.drug, Lenalidomide
Published
2017
Full Text
View/download PDF

46. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group

Author

Gilles Salles, F. Morschhauser, Lucie Oberic, T. Lamy, Caroline Dartigeas, Ghandi Damaj, H. Maisonneuve, S. Le Gouill, O. Casasnovas, H. Tilly, K. le Dû, Olivier Hermine, Hacene Zerazhi, Thomas Gastinne, O. Tournilhac, P. Feugier, E. Van Den Neste, Vincent Ribrag, Corinne Haioun, Remy Gressin, Luc Mathieu Fornecker, Anne-Sophie Moreau, Kamal Bouabdallah, Guillaume Cartron, and Catherine Thieblemont

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Surgery, Autologous stem-cell transplantation, Oncology, medicine, Mantle cell lymphoma, Rituximab, In patient, business, medicine.drug
Published
2017
Full Text
View/download PDF

47. First‐line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study

Author

Meunier, Godelieve, primary, Ysebaert, Loic, additional, Nguyen‐Thi, Phi Linh, additional, Lepretre, Stéphane, additional, Quinquenel, Anne, additional, Dupuis, Jehan, additional, Lemal, Richard, additional, Aurran, Thérèse, additional, Tomowiak, Cécile, additional, Cymbalista, Florence, additional, Dilhuydy, Marie Sarah, additional, Brion, Annie, additional, Morel, Pierre, additional, Cazin, Bruno, additional, Leblond, Véronique, additional, Cartron, Guillaume, additional, Ré, Daniel, additional, Béné, Marie Christine, additional, Michallet, Anne Sophie, additional, and Feugier, Pierre, additional

Published
2016
Full Text
View/download PDF

48. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Author

Meunier, Godelieve, Ysebaert, Loic, Nguyen‐Thi, Phi Linh, Lepretre, Stéphane, Quinquenel, Anne, Dupuis, Jehan, Lemal, Richard, Aurran, Thérèse, Tomowiak, Cécile, Cymbalista, Florence, Dilhuydy, Marie Sarah, Brion, Annie, Morel, Pierre, Cazin, Bruno, Leblond, Véronique, Cartron, Guillaume, Ré, Daniel, Béné, Marie Christine, Michallet, Anne Sophie, and Feugier, Pierre

Subjects
CHRONIC lymphocytic leukemia diagnosis, AGE distribution, ANTINEOPLASTIC agents, CHROMOSOME abnormalities, CHRONIC lymphocytic leukemia, GENETIC mutation, PROGNOSIS, SURVIVAL analysis (Biometry), TUMOR classification, SOCIOECONOMIC factors, TREATMENT effectiveness, RETROSPECTIVE studies
Abstract

The mean age at diagnosis of chronic lymphocytic leukemia (CLL) is 72 years, with 22.8% of patients being older than 80 years. However, the elderly are underrepresented in clinical studies of CLL. We performed a retrospective study of CLL patients aged 80 years or older at the initiation of first-line therapy in hospitals affiliated with the French intergroup on CLL (French Innovative Leukemia Organization) between 2003 and 2013. Here, we describe the clinical and biological characteristics, treatment, and outcomes for 201 patients. The median age of the cohort was 83.2 years (80-92 years). The median Cumulative Index Rating Scale comorbidity score was 5 and the median creatinine clearance was 48 mL/min (Cockcroft-Gault formula). At treatment initiation, Binet stage was A (26.4%), B (27.9%), or C (40.3%). Therapy consisted mainly of chlorambucil (65.7%), bendamustine (10.5%), and rituximab (44.3%) as follows: chlorambucil alone (45.3%) or immunochemotherapy (48.3%) with rituximab + chlorambucil (22.7%), rituximab + bendamustine (10.4%), or rituximab + cyclophosphamide + dexamethasone (5.5%). The overall response rate was 66.2% with 31.8% clinical complete remission. The median overall and progression-free survival from treatment initiation was 53.7 and 18.3 months, respectively. These results suggest that treatment is feasible in this age group, even with immunochemotherapy. Thus, prospective trials should target this population and oncogeriatric evaluation and new targeted therapies should be part of such future trials. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results